Pharma Industry News

Withdrawal symptoms: Pharmaceutical firms trigger contingency plans for a no-deal Brexit

Written by David Miller

Print section
Print Rubric: 

Pharma firms trigger their contingency plans for a no-deal Brexit

Print Headline: 

Withdrawal symptoms

Print Fly Title: 

Brexit and pharmaceuticals

UK Only Article: 
standard article

Issue: 

The army sidelines Robert Mugabe, Africa’s great dictator

Fly Title: 

Withdrawal symptoms

Main image: 

20171118_BRP002_0.jpg

ONE of the first tangible consequences of Britain’s exit from the European Union will be made clear on November 20th, when the EU announces the new home of its drug regulator, the European Medicines Agency, which is currently based in London. The agency will have less than 17 months to pack its bags before Britain leaves the EU in March 2019, whereas by its own reckoning it needs a transition period of at least two to three years.
The agency’s relocation is not the only worry facing one of Britain’s most important and most …Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]